Renato D Lopes

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial
    Renato D Lopes
    Duke Clinical Research Institute, Box 3850, 2400 Pratt Street, Room 311, Terrace Level, Durham, NC 27705, USA
    Eur Heart J 29:1827-33. 2008
  2. ncbi request reprint Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am J Med 125:897-905. 2012
  3. pmc Do omega-3 fatty acids prevent atrial fibrillation after open heart surgery? A meta-analysis of randomized controlled trials
    Luciana Armaganijan
    Electrophysiology and Cardiac Arrhythmias, Dante Pazzanese Institute of Cardiology, Sao Paulo, SP, Brazil
    Clinics (Sao Paulo) 66:1923-8. 2011
  4. doi request reprint Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes
    Renato D Lopes
    Duke Clinical Research Institute, Durham, NC, USA Electronic address
    Int J Cardiol 168:2510-7. 2013
  5. doi request reprint Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial
    Renato D Lopes
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Int J Cardiol 167:2580-7. 2013
  6. doi request reprint Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 166:208-216.e28. 2013
  7. pmc Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311, Terrace Level, Box 3850, Durham, NC 27705, USA
    Trials 14:123. 2013
  8. doi request reprint Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, P O Box 3850, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA
    J Thromb Thrombolysis 36:115-30. 2013
  9. doi request reprint Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Blood 118:6269-73. 2011
  10. doi request reprint Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Lancet 380:1749-58. 2012

Collaborators

Detail Information

Publications80

  1. ncbi request reprint Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial
    Renato D Lopes
    Duke Clinical Research Institute, Box 3850, 2400 Pratt Street, Room 311, Terrace Level, Durham, NC 27705, USA
    Eur Heart J 29:1827-33. 2008
    ..The SYNERGY database was used to study the influence of age on treatment outcomes with enoxaparin vs. unfractionated heparin (UFH) in patients with high-risk NSTE ACS...
  2. ncbi request reprint Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am J Med 125:897-905. 2012
    ..Atrial fibrillation guidelines recommend long-term use of warfarin according to a patient's predicted risk of stroke. After acute myocardial infarction, however, combining warfarin and antiplatelet medications poses challenges...
  3. pmc Do omega-3 fatty acids prevent atrial fibrillation after open heart surgery? A meta-analysis of randomized controlled trials
    Luciana Armaganijan
    Electrophysiology and Cardiac Arrhythmias, Dante Pazzanese Institute of Cardiology, Sao Paulo, SP, Brazil
    Clinics (Sao Paulo) 66:1923-8. 2011
    ..However, randomized studies have yielded conflicting results. The objective of this study is to review randomized trials of N-3 polyunsaturated fatty acid use for postoperative atrial fibrillation...
  4. doi request reprint Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes
    Renato D Lopes
    Duke Clinical Research Institute, Durham, NC, USA Electronic address
    Int J Cardiol 168:2510-7. 2013
    ....
  5. doi request reprint Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial
    Renato D Lopes
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Int J Cardiol 167:2580-7. 2013
    ..We evaluated the efficacy and safety of intensive treatment with glycoprotein IIb/IIIa inhibitors in an elderly population, and the relationships between age, timing of administration, and clinical outcomes...
  6. doi request reprint Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 166:208-216.e28. 2013
    ..In 2010, after regulatory review of rosiglitazone licensing, the US Food and Drug Administration (FDA) requested a reevaluation of cardiovascular end points in the RECORD trial...
  7. pmc Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311, Terrace Level, Box 3850, Durham, NC 27705, USA
    Trials 14:123. 2013
    ..We evaluated alternative approaches to quantifying infarct size using CK-MB values, and the relationship between infarct size and clinical outcomes...
  8. doi request reprint Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, P O Box 3850, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA
    J Thromb Thrombolysis 36:115-30. 2013
    ..This paper summarizes the symposium proceedings...
  9. doi request reprint Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Blood 118:6269-73. 2011
    ..You recall a potential interaction and wonder if (1) her acetaminophen use is contributing to her loss of INR control, and (2) does this interaction place her at increased risk of warfarin-related complications?..
  10. doi request reprint Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Lancet 380:1749-58. 2012
    ..We assessed in this trial's participants how results differed according to patients' CHADS(2), CHA(2)DS(2)VASc, and HAS-BLED scores, used to predict the risk of stroke and bleeding...
  11. pmc The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction
    Renato D Lopes
    Duke Clinical Research Institute, Box 3850, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA
    Eur Heart J 33:2044-53. 2012
    ..Their association with long-term outcomes is less clear. This study examines mortality associated with in-hospital bleeding during NSTEMI over time intervals starting from hospital discharge and extending past 3 years...
  12. doi request reprint Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Box 3850, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27705, USA
    J Thromb Thrombolysis 34:143-63. 2012
    ..This paper summarizes the symposium proceedings...
  13. pmc Bilateral macular hemorrhage as a complication of drug-induced anemia: a case report
    Rubens N Belfort
    Henry C Witelson Ocular Pathology Laboratory, Ophthalmology Department, McGill University, Montreal, QC, Canada
    J Med Case Reports 3:16. 2009
    ..Bilateral macular hemorrhage is a rare ocular finding and to the best of our knowledge, this is the first report of such hemorrhages as a presentation of drug-induced anemia...
  14. doi request reprint Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial
    Renato D Lopes
    Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 53:1021-30. 2009
    ....
  15. doi request reprint Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    JACC Cardiovasc Interv 3:669-77. 2010
    ..The aim of this study was to examine the use of and outcomes associated with antithrombotic strategies in patients with non-ST-segment elevation myocardial infarction (NSTEMI) who undergo percutaneous coronary intervention (PCI)...
  16. doi request reprint Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry
    Renato D Lopes
    Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA
    Stroke 42:3477-83. 2011
    ..However, few studies have examined factors associated with long-term antithrombotic therapy use in IS/TIA patients with AF...
  17. doi request reprint Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Box 3850, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA
    J Thromb Thrombolysis 32:242-66. 2011
    ..This paper summarizes the symposium proceedings...
  18. doi request reprint Antiplatelet agents in cardiovascular disease
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Box 3850, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA
    J Thromb Thrombolysis 31:306-9. 2011
    ..In this article, we review the new antiplatelet agents being developed as well as their pharmacological characteristics, potential clinical indications, and key interactions with other antithrombotic drugs...
  19. doi request reprint Antiplatelet therapy in older adults with non-ST-segment elevation acute coronary syndrome: considering risks and benefits
    Renato D Lopes
    Duke University Medical Center, 2400 Pratt Street, Terrace Level, Durham, NC 27705, USA
    Am J Cardiol 104:16C-21C. 2009
    ..However, given their complexity, it is important to further consider the application of existing and new therapies and strategies of care in "real-world" settings...
  20. ncbi request reprint Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry)
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 104:1285-91. 2009
    ..98, p = 0.03). In conclusion, the 6-month mortality rate among heparin-treated patients with thrombocytopenia is high, although the risk independently related to thrombocytopenia appears to be restricted to the acute hospital phase...
  21. doi request reprint Diagnosing acute myocardial infarction in patients with left bundle branch block
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 108:782-8. 2011
    ....
  22. pmc Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients
    Connie N Hess
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 164:607-15. 2012
    ..Balancing safe and effective use of aspirin, clopidogrel, and warfarin in this population is important...
  23. doi request reprint Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy
    Emil L Fosbol
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC The Heart Centre, University Hospital of Copenhagen, Rigshospitalet, Denmark Electronic address
    Am Heart J 166:864-70. 2013
    ..We sought to determine the risk of readmission for bleeding and major cardiac events in stented non-ST-segment elevation myocardial infarction (NSTEMI) atrial fibrillation (AF) patients...
  24. pmc Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry
    Benjamin A Steinberg
    MPH, Duke University Medical Center and Duke Clinical Research Institute, 2400 Pratt St, Ste 7009, Durham, NC 27705, USA
    Circulation 128:721-8. 2013
    ..We assessed concomitant ASA use and its association with clinical outcomes among AF patients treated with OAC...
  25. pmc Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, DUMC Box 3850, Durham, NC 27705, USA
    Circulation 125:749-56. 2012
    ..In this retrospective analysis, we examined the relationship between VGF, assessed by coronary angiography 12 to 18 months after coronary artery bypass graft surgery, and subsequent clinical outcomes...
  26. doi request reprint Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 163:797-803. 2012
    ..Information on practice patterns and outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary interventions (PCIs) in Canada vs United States is limited...
  27. doi request reprint Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial
    Sana M Al-Khatib
    Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    Eur Heart J 34:2464-71. 2013
    ..It is uncertain whether the benefit from apixaban varies by type and duration of atrial fibrillation (AF)...
  28. doi request reprint Apixaban versus warfarin in patients with atrial fibrillation
    Christopher B Granger
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 365:981-92. 2011
    ..Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin...
  29. doi request reprint Results of a reevaluation of cardiovascular outcomes in the RECORD trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 166:240-249.e1. 2013
    ..This provided an opportunity to assess the implications of event adjudication by 2 groups and quantify the differences as well as to use new FDA end point definitions in development...
  30. pmc Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients
    Sunil V Rao
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    JACC Cardiovasc Interv 5:958-65. 2012
    ..The authors sought to describe the association between post-procedural bleeding and long-term recurrent bleeding, major adverse cardiac events (MACE), and mortality among older patients undergoing percutaneous coronary intervention (PCI)...
  31. doi request reprint Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 159:331-9. 2010
    ....
  32. ncbi request reprint Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction
    Emil L Fosbol
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 163:720-8. 2012
    ..We aimed to study the comparative safety and effectiveness of various antithrombotic treatment strategies among older adults with non-ST elevation myocardial infarction (NSTEMI) and atrial fibrillation (AF)...
  33. ncbi request reprint Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 109:320-6. 2012
    ..These data highlight the importance of understanding factors associated with gender-related differences in bleeding and represent an opportunity for improving outcomes of women and men with fibrinolytic-treated STEMI...
  34. ncbi request reprint Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting
    Judson B Williams
    Duke Clinical Research Institute, Durham, NC, USA
    J Thromb Thrombolysis 36:384-93. 2013
    ..There may be better outcomes with clopidogrel among patients having off-pump surgery. Adequately powered randomized clinical trials are needed to determine the role of dual antiplatelet therapy after CABG...
  35. pmc Hospital length of stay in patients with non-ST-segment elevation myocardial infarction
    John P Vavalle
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am J Med 125:1085-94. 2012
    ..Substantial heterogeneity in hospital length of stay exists among patients admitted with non-ST-segment elevation myocardial infarction. Furthermore, little is known about the factors that impact length of stay...
  36. ncbi request reprint Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia
    E Marc Jolicoeur
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    Curr Cardiol Rep 9:396-405. 2007
    ..The algorithm also integrates preventive measures directed at decreasing the bleeding risk associated with the antithrombotic and invasive therapies used for HIT and percutaneous coronary intervention...
  37. pmc Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results
    Renato D Lopes
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 164:379-386.e1. 2012
    ..We compared the 5-year clinical outcomes of patients in PREVENT IV treated with edifoligide and placebo to identify predictors of long-term clinical outcomes...
  38. ncbi request reprint Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am J Med 123:134-40. 2010
    ....
  39. doi request reprint Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial
    Rajendra H Mehta
    Duke Clinical Research Institute, Box 17969, Durham, NC 27715, USA
    Circulation 124:280-8. 2011
    ....
  40. doi request reprint Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry
    Sumeet Subherwal
    Duke University, 2500 Pratt St, Durham, NC 27715, USA
    Circulation 125:1414-23. 2012
    ..Yet, little is known about contemporary treatment patterns and bleeding risks in this population...
  41. pmc International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation
    Jorge Suarez
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am Heart J 163:804-11. 2012
    ..We sought to characterize patient factors and regional variations associated with vitamin K antagonist (VKA) use in patients with heart failure (HF) and atrial fibrillation (AF) in areas outside the United States and Europe...
  42. doi request reprint Impact of extracardiac vascular disease on vein graft failure and outcomes after coronary artery bypass surgery
    Ralf E Harskamp
    Duke Clinical Research Institute, Durham, North Carolina Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Ann Thorac Surg 97:824-30. 2014
    ....
  43. doi request reprint Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial
    Sergio Leonardi
    Department of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    Coron Artery Dis 24:321-7. 2013
    ..Using data from the CHAMPION percutaneous coronary intervention (PCI), we determined the relationship between clopidogrel started at least 5 days before PCI (maintenance of clopidogrel) and PCI-related enzymatic infarct size...
  44. doi request reprint Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am J Med 124:48-57. 2011
    ....
  45. pmc Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insights
    Sean van Diepen
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Circ Cardiovasc Qual Outcomes 5:437-44. 2012
    ..We examined the association between door 1-to-door 2 (D1D2) time, a measure capturing the entire transfer process, and outcomes in patients undergoing interhospital transfer for primary percutaneous coronary intervention...
  46. pmc Serious infection after acute myocardial infarction: incidence, clinical features, and outcomes
    Adriano A M Truffa
    Duke Clinical Research Institute and the Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Durham, NC 27705, USA
    JACC Cardiovasc Interv 5:769-76. 2012
    ..We also assessed the association between serious infections and 90-day death or death/myocardial infarction (MI)...
  47. doi request reprint Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: timing, characteristics, and clinical outcomes
    Jeffrey T Guptill
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Circ Cardiovasc Interv 6:176-83. 2013
    ..Little is known about stroke timing, characteristics, and clinical outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention (PCI)...
  48. ncbi request reprint Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012
    Adriano A Truffa
    Duke Clinical Research Institute and the Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC 27705, USA
    Postgrad Med 125:146-57. 2013
    ..This article reviews the anticoagulant agents that are clinically available or under development as alternatives to VKAs for stroke prevention in patients with nonvalvular atrial fibrillation. ..
  49. ncbi request reprint Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Curr Opin Cardiol 25:312-20. 2010
    ..Consequently, much research has been focused on finding an alternative to warfarin. We review the potential alternatives in development and evaluate the current evidence concerning their safety and efficacy...
  50. doi request reprint Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome
    Roberto R Giraldez
    Instituto do Coracao Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo and the Brazilian Clinical Research Institute, Sao Paulo, Brazil
    Am Heart J 165:918-925.e2. 2013
    ..We examined the prevalence of undiagnosed diabetes or prediabetes and associations with ischemic outcomes among non-ST-segment elevation acute coronary syndrome (ACS) patients...
  51. doi request reprint Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial
    Sean van Diepen
    Duke Clinical Research Institute, Duke University Medical Center, North Pavilion, 2400 Pratt Street, Durham, NC 27705, USA
    J Thromb Thrombolysis 34:106-13. 2012
    ..This finding is consistent with pre-clinical and clinical research suggesting that systemic inflammation may influence NT-proBNP expression independently of myocardial stretch...
  52. doi request reprint Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study
    Akshay Bagai
    Duke Clinical Research Institute, Durham, NC Electronic address
    Am Heart J 166:913-9. 2013
    ..We sought to determine the prognostic value of LVEDP measured during primary PCI for ST-segment elevation myocardial infarction (STEMI)...
  53. doi request reprint International variation in and factors associated with hospital readmission after myocardial infarction
    Robb D Kociol
    Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    JAMA 307:66-74. 2012
    ..Recently, 30-day readmission rates have been proposed as a metric for care of patients with STEMI. However, international rates and predictors of 30-day readmission after STEMI have not been studied...
  54. doi request reprint Promise of factor Xa inhibition in atrial fibrillation
    Sana M Al-Khatib
    Division of Cardiology, Department of Medicine, Duke Clinical Research Institute and Duke University, 2400 Pratt Street, PO Box 17969, Durham, NC 27705, USA
    Curr Cardiol Rep 14:70-8. 2012
    ....
  55. doi request reprint Surgical Maze procedure as a treatment for atrial fibrillation: a meta-analysis of randomized controlled trials
    Melissa H Kong
    Duke University Medical Center, Durham, NC 27710, USA
    Cardiovasc Ther 28:311-26. 2010
    ..Large RCTs defining rates of freedom from AF without AADs postprocedure, are still needed to evaluate outcomes and determine the appropriate role for surgical Maze procedures in the management of AF...
  56. doi request reprint Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy
    Sean van Diepen
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada Electronic address
    Int J Cardiol 168:2127-33. 2013
    ..Whether STEMI clinical prediction models can be improved with the addition of baseline inflammatory biomarkers remains unknown...
  57. doi request reprint Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction
    Sergio Leonardi
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 60:2296-304. 2012
    ..This study compared prognoses of myocardial infarction related to percutaneous coronary intervention (PCI, procedural MI) using increasing creatine kinase-myocardial band (CK-MB) thresholds with spontaneous MI...
  58. pmc Association between endoscopic vs open vein-graft harvesting and mortality, wound complications, and cardiovascular events in patients undergoing CABG surgery
    Judson B Williams
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    JAMA 308:475-84. 2012
    ..The safety and durability of endoscopic vein graft harvest in coronary artery bypass graft (CABG) surgery has recently been called into question...
  59. doi request reprint Apixaban with antiplatelet therapy after acute coronary syndrome
    John H Alexander
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 365:699-708. 2011
    ..Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome...
  60. pmc Relationship of the time interval between cardiac catheterization and elective coronary artery bypass surgery with postprocedural acute kidney injury
    Rajendra H Mehta
    Duke Clinical Research Institute, Box 17969, Durham, NC 27715, USA
    Circulation 124:S149-55. 2011
    ..However, these studies, because of the small number of patients, were unable to adequately account for patient case-mix and included both those undergoing elective surgery and those undergoing urgent surgery...
  61. doi request reprint Relationship of sustained ventricular tachyarrhythmias to outcomes in patients undergoing primary percutaneous coronary intervention with varying underlying baseline risk
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 161:782-9. 2011
    ....
  62. doi request reprint Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 361:235-44. 2009
    ....
  63. pmc Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27707, USA
    Eur Heart J 30:2019-28. 2009
    ..To assess the incidence and timing of atrial fibrillation (AF), describe antithrombotic therapy use, and evaluate the association of AF with 90 day mortality and other secondary clinical outcomes...
  64. doi request reprint Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention
    Rajendra H Mehta
    Duke Clinical Research Institute, Box 17969, Durham, NC 27715, USA
    JAMA 301:1779-89. 2009
    ....
  65. doi request reprint Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician
    Connie N Hess
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311 Terrace Level, Box 3850, Durham, NC 27705, USA
    J Thromb Thrombolysis 34:552-61. 2012
    ..We provide a review of the clinical syndrome and practical summary of treatment recommendations from the most recent 2012 American College of Chest Physicians evidence-based guidelines for the treatment and prevention of HIT...
  66. ncbi request reprint Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease?
    Rajendra H Mehta
    The Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 159:141-7. 2010
    ..Although both percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are used in patients with CS with multivessel coronary disease, the optimal revascularization strategy in this setting remains unknown...
  67. doi request reprint Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions
    Ralf E Harskamp
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Ann Surg 257:824-33. 2013
    ..To review our current understanding of the epidemiology and pathogenesis of vein graft failure (VGF), give an overview of current preventive and interventional measures, and explore strategies that may improve vein graft patency...
  68. doi request reprint Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Thromb Thrombolysis 26:167-74. 2008
    ....
  69. doi request reprint Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials
    Jonathan P Piccini
    Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Circ Arrhythm Electrophysiol 2:626-33. 2009
    ..The efficacy and safety of pulmonary vein isolation (PVI) compared with medical therapy remain in question...
  70. doi request reprint Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23-25, 2008, Sao Paulo, Brazil
    Renato D Lopes
    Duke University School of Medicine, Durham, NC, USA
    J Thromb Thrombolysis 28:106-16. 2009
    ..This article is a focused summary of the symposium proceedings...
  71. ncbi request reprint Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician
    S Michael Gharacholou
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Thromb Thrombolysis 29:516-28. 2010
    ....
  72. doi request reprint Impact of recovery of renal function on long-term mortality after coronary artery bypass grafting
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 106:1728-34. 2010
    ..Thus, major emphasis should be on prevention of ARF in patients undergoing CABG...
  73. doi request reprint Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF
    Jonathan P Piccini
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 162:606-612.e1. 2011
    ..Data on contemporary treatment patterns and outcomes associated with AF in clinical practice are limited...
  74. pmc Saphenous vein graft failure and clinical outcomes: Toward a surrogate end point in patients following coronary artery bypass surgery?
    Ralf E Harskamp
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Am Heart J 165:639-43. 2013
    ..Given the lack of supportive evidence showing a consistent association between SVG failure and major adverse cardiovascular events, SVG failure should not be considered a valid surrogate endpoint at this time...
  75. doi request reprint Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial
    Sunil V Rao
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 121:1713-21. 2010
    ..We performed a phase 2 randomized trial to evaluate the safety and feasibility of M118 in the setting of elective percutaneous coronary intervention...
  76. doi request reprint Age and outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: findings from the APEX-AMI trial
    S Michael Gharacholou
    Division of Cardiology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Arch Intern Med 171:559-67. 2011
    ....
  77. doi request reprint Antithrombotic therapy for ischemic stroke: guidelines translated for the clinician
    Anandi Krishnan
    Duke Clinical Research Institute, Duke University Medical Center, Box 3850, 27710, Durham, NC, USA
    J Thromb Thrombolysis 29:368-77. 2010
    ..Future directions are also reviewed, with particular emphasis on improving therapeutic options early after stroke onset...
  78. doi request reprint Prophylaxis for venous thromboembolism: guidelines translated for the clinician
    Gregg Stashenko
    Duke Clinical Research Institute, Duke University Medical Center, Box 3850, Durham, NC 27710, USA
    J Thromb Thrombolysis 31:122-32. 2011
    ..In addition, we will discuss recent clinical trials regarding novel anticoagulants for venous thromboembolism prophylaxis and share some conclusions...
  79. doi request reprint The safety and efficacy of apixaban : where do we stand in 2013?
    Flavio de Souza Brito
    Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA
    Expert Opin Drug Saf 12:559-67. 2013
    ..We reviewed the pharmacokinetics and pharmacology as well as the clinical safety and efficacy of apixaban , an oral direct factor Xa inhibitor...
  80. ncbi request reprint Highlights from the 56th annual scientific sessions of the American College of Cardiology: March 25 to 27, 2007, Atlanta, Georgia
    George L Adams
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 154:247-59. 2007